The direct renin inhibitor aliskiren offers a novel strategy for more complete RAAS blockade in hypertension, potentially reducing adverse events compared to dual ACEI and ARB therapy.
Does the use of direct renin inhibitors (aliskiren) alone or in combination provide effective RAAS blockade with fewer adverse events compared to traditional ACEI/ARB therapies?
Direct renin inhibitors like aliskiren represent a promising strategy for comprehensive RAAS blockade in hypertension management, potentially avoiding the adverse effects seen with ACEI/ARB combinations.
The renin-angiotensin-aldosterone system (RAAS), an important regulator of blood pressure and mediator of hypertension-related complications, is a prime target for cardiovascular drug therapy. Angiotensin-converting enzyme inhibitors (ACEIs) were the first drugs to be used to block the RAAS. Angiotensin II receptor blockers (ARBs) have also been shown to be equally effective for treatment. Although these drugs are highly effective and are widely used in the management of hypertension, current treatment regimens with ACEIs and ARBs are unable to completely suppress the RAAS. Combinations of ACEIs and ARBs have been shown to be superior than to either agent alone for some, but certainly not all, composite cardiovascular and kidney outcomes, but dual RAAS blockade with the combination of an ACEI and an ARB is sometimes associated with an increase in the risk for adverse events, primarily hyperkalemia and worsening renal function. The recent introduction of the direct renin inhibitor, aliskiren, has made available new combination strategies to obtain a more complete blockade of the RAAS with fewer adverse events. Renin system blockade with aliskiren and another RAAS agent has been, and still is, the subject of many large-scale clinical trials and furthermore, is already available in some countries as a fixed combination.
Francesca Cagnoni (Tue,) conducted a review in Hypertension. Aliskiren (direct renin inhibitor) vs. ACEIs and ARBs was evaluated. The direct renin inhibitor aliskiren offers a novel strategy for more complete RAAS blockade in hypertension, potentially reducing adverse events compared to dual ACEI and ARB therapy.